Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Grifols Biomat Employee Portal"

14:31 EDT 18th April 2014 | BioPortfolio

Original Source: Grifols, Inc.

Currently, we supply plasma products, diagnostic reagents, automated analyzers and dosing machines.In 1998, Grifols established a joint venture with a US diagnostic company, Quest International. Then, in 2000 in order to prepare for an even greater presence in the USA with its plasma products, Grifols founded Grifols USA.Grifols acquired SeraCare’s network of 45 plasmapheresis centers in 2002, thereby vertically integrating the company and guaranteeing its supply of plasma. A year later, Grifols acquired...

Matching Channels

Matching News

Grifols: M&A activity 2005-2014

Grifols, listed as a big pharma and big biotech company, has announced 4 M&A deals since 2005, with the lead deals being the acquisitions of Tacleris Pharmaceuticals. Abstracted from: Partnering A...

Axion Health™ Releases New 'Supervisor' Feature for ReadySet™ Employee Well-being Software

WESTMINSTER, Colo., Nov. 21, 2013 /PRNewswire/ -- Axion Health is proud to announce the release of the highly anticipated 'Supervisor Portal' feature for its ReadySetTM employee well-being software so...

Annual Report for 2013 on Form 20-F filed with the SEC on April 4, 2014

BARCELONA, Spain, April 4, 2014 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), announced that it has filed its 2013 Annual Report on Form 20-F with the United Sta...

Grifols: Keeping the world’s blood supply pumping

Grifols is a Spanish global pharmaceutical company specialising in the supply of blood plasma products. The company has three primary divisions: Bioscience, Diagnostic and Hospital that together devel...

Spain's Grifols completes $5.5 bln refinancing

MADRID, March 17 (Reuters) - Spanish blood products company Grifols said on Monday in a statement to the stock market regulator that it had finalised a $5.5 billion debt restructuring plan.

Grifols: Partnering activity 2005-2013

Grifols, a global healthcare company, listed as big biotech and big pharma company aims to improve health and well-being of the people. Analysis of the deals since 2005 shows partnering in the areas o...

How to Use a Patient Portal

As more and more physicians’ offices and other providers begin to take the first step in setting up a patient portal, I thought it would be interesting to tell our story about how our office impleme...

Grifols chairman backs Catalan independence movement

MADRID, April 3 (Reuters) - The head of Spain's largest pharmaceutical company, Grifols, on Thursday became one of the first executives of a major corporation to back a Catalan leader seeking a refere...

Matching PubMed Articles

Portal hypertension: A critical appraisal of shunt procedures with emphasis on distal splenorenal shunt in children.

Extrahepatic portal venous obstruction (EHPVO) is the most common cause of pediatric portal hypertension. We analyzed the investigative protocol and results of portosystemic shunts in this group of pa...

Portal inflow preservation during portal diversion in small-for-size syndrome.

To investigate the impact of portal inflow on liver remnants in a stable pig model of small-for-size syndrome.

The p-medicine portal-a collaboration platform for research in personalised medicine.

The European project p-medicine creates an information technology infrastructure that facilitates the development from current medical practice to personalised medicine. The main access point to this...

Rapamycin Ameliorates Inflammation and Fibrosis in the Early Phase of Cirrhotic Portal Hypertension in Rats through Inhibition of mTORC1 but Not mTORC2.

Hepatic stellate cells (HSCs) transdifferentiation and subsequent inflammation are important pathological processes involved in the formation of cirrhotic portal hypertension. This study characterizes...

Is it tea time for portal hypertension?

Portal hypertension is the main complication of cirrhosis and represents a leading cause of death in patients with chronic liver disease. Therapeutic agents to improve portal hypertension should ameli...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement